Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation

Journal of Internal Medicine

Volumn 278, Issue 1, 2015, Pages 1-18

  Shields, A M ^a   Lip, Gregory Y H ^b,c  

^a MAYDAY UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c AALBORG UNIVERSITY   (Denmark)

Author keywords

Anticoagulation; Atrial fibrillation; NOAC; Stroke; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN; ANTICOAGULANTS; VITAMIN K;

AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ASIAN; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; HUMAN; KIDNEY FAILURE; META ANALYSIS (TOPIC); PATIENT PREFERENCE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRANSIENT ISCHEMIC ATTACK; ADMINISTRATION, ORAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMPLICATION; HEMORRHAGE; HUMANS; PATIENT-CENTERED CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; STROKE;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; HEMORRHAGE; HUMANS; PATIENT-CENTERED CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; STROKE; VITAMIN K; WARFARIN;

EID: 84930928829     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12360     Document Type: Review

References (122)

1. Lip GY, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest 2012; 142: 1489-98.
2. Naccarelli GV, Varker H, Lin J et al. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009; 104: 1534-9.
3. Kim MH, Johnston SS, Chu BC et al. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes 2011; 4: 313-20.
4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-8.
5. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J 2010; 31: 967-75.
6. Lloyd-Jones D, Adams RJ, Brown TM et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010; 121: e46-215.
7. Chao TF, Huang YC, Liu CJ et al. Acute myocardial infarction in patients with atrial fibrillation with a CHADS-VASc score of 0 or 1: a nationwide cohort study. Heart Rhythm 2014; 11: 1941-7.
8. Kilander L, Andren B, Nyman H et al. Atrial fibrillation is an independent determinant of low cognitive function: a cross-sectional study in elderly men. Stroke 1998; 29: 1816-20.
9. Stewart S, Hart CL, Hole DJ et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113: 359-64.
10. Benjamin EJ, Wolf PA, D'Agostino RB et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98: 946-52.
11. Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2007;(3): CD006186.
12. van Walraven C, Hart RG, Singer DE et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002; 288: 2441-8.
13. Ogilvie IM, Welner SA, Cowell W et al. Ischaemic stroke and bleeding rates in 'real-world' atrial fibrillation patients. Thromb Haemost 2011; 106: 34-44.
14. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-67.
15. NICE. Atrial fibrillation: the management of atrial fibrillation. NICE 2014. Available at: www.nice.org.uk
16. European Heart Rhythm A, European Association for Cardio-Thoracic S, Camm AJ et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12: 1360-420.
17. Investigators AF. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-57.
18. Lip GY, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-72.
19. Lip GY, Haguenoer K, Saint-Etienne C et al. Relationship of the SAME-TT2R2score to poor quality anticoagulation, stroke, clinically relevant bleeding and mortality in patients with atrial fibrillation. Chest 2014; 146: 719-26.
20. Pisters R, Lane DA, Nieuwlaat R et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-100.
21. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
22. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.
23. Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-104.
24. Connolly SJ, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-17.
25. Holbrook AM, Pereira JA, Labiris R et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165: 1095-106.
26. Aithal GP, Day CP, Kesteven PJ et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-9.
27. D'Andrea G, D'Ambrosio RL, Di Perna P et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105: 645-9.
28. Husted S, de Caterina R, Andreotti F et al. Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel. Thromb Haemost 2014; 111: 781-2.
29. Yeh CH, Fredenburgh JC, Weitz JI. Oral direct factor Xa inhibitors. Circ Res 2012; 111: 1069-78.
30. Lee CJ, Ansell JE. Direct thrombin inhibitors. Br J Clin Pharmacol 2011; 72: 581-92.
31. De Caterina R, Husted S, Wallentin L et al. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 109: 569-79.
32. Ruff CT, Giugliano RP, Braunwald E et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-62.
33. Salazar CA, del Aguila D, Cordova EG. Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. Cochrane Database Syst Rev 2014;(3): CD009893.
34. Bruins Slot KM, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database Syst Rev 2013;(8): CD008980.
35. Skjoth F, Larsen TB, Rasmussen LH et al. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thromb Haemost 2014; 111: 981-8.
36. Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-70.
37. Karthikeyan G, Eikelboom JW. The CHADS2 score for stroke risk stratification in atrial fibrillation-friend or foe? Thromb Haemost 2010; 104: 45-8.
38. Olesen JB, Torp-Pedersen C, Hansen ML et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost 2012; 107: 1172-9.
39. Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-47.
40. Oldgren J, Ezekowitz JA, Alings M et al. Dabigatran versus warfarin and impact of CHAD2-VASC score on outcome in atrial fibrillation patients: a RE-LY subgroup analysis (Abstract). J Am Coll Cardiol 2011; 57: E7.
41. Lopes RD, Al-Khatib SM, Wallentin L et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet 2012; 380: 1749-58.
42. Banerjee A, Lane DA, Torp-Pedersen C et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012; 107: 584-9.
43. Fang MC, Go AS, Chang Y et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011; 58: 395-401.
44. Gage BF, Yan Y, Milligan PE et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151: 713-9.
45. Apostolakis S, Lane DA, Guo Y et al. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol 2012; 60: 861-7.
46. Roldan V, Marin F, Fernandez H et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy. Chest 2013; 143: 179-84.
47. Lane DA, Lip GY. Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation 2012; 126: 860-5.
48. Connolly SJ, Pogue J, Eikelboom J et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029-37.
49. De Caterina R, Husted S, Wallentin L et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: 1087-107.
50. Baczek VL, Chen WT, Kluger J et al. Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis. BMC Fam Pract 2012; 13: 5.
51. Wan Y, Heneghan C, Perera R et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008; 1: 84-91.
52. Morgan CL, McEwan P, Tukiendorf A et al. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res 2009; 124: 37-41.
53. Gallego P, Roldan V, Marin F et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013; 110: 1189-98.
54. Razouki Z, Ozonoff A, Zhao S et al. Pathways to poor anticoagulation control. J Thromb Haemost 2014; 12: 628-34.
55. Apostolakis S, Sullivan RM, Olshansky B et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest 2013; 144: 1555-63.
56. Gallego P, Roldan V, Marin F et al. SAME-TTR score, time in therapeutic range and outcomes in anticoagulated patients with atrial fibrillation. Am J Med 2014; 127: 1083-8.
57. Azoulay L, Dell'Aniello S, Simon TA et al. Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. Eur Heart J 2014; 35: 1881-7.
58. Skjoth F, Larsen TB, Rasmussen LH. Indirect comparison studies-are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillation. Thromb Haemost 2012; 108: 405-6.
59. Harenberg J, Marx S, Wehling M. Head-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: what's next? Thromb Haemost 2012; 108: 407-9.
60. Kansal AR, Sharma M, Bradley-Kennedy C et al. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness. Thromb Haemost 2012; 108: 672-82.
61. Friberg L, Benson L, Lip GY. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. Eur Heart J 2015; 36: 297-306.
62. Kooiman J, van de Peppel WR, van der Meer FJ et al. Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs. J Thromb Haemost 2011; 9: 1652-3.
63. Chao TF, Liu CJ, Wang KL et al. Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis. Heart Rhythm 2014; 11: 1752-9.
64. Kooiman J, van Rein N, Spaans B et al. Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease. PLoS One 2014; 9: e94420.
65. Hijazi Z, Hohnloser SH, Oldgren J et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014; 129: 961-70.
66. Legrand M, Mateo J, Aribaud A et al. The use of dabigatran in elderly patients. Arch Intern Med 2011; 171: 1285-6.
67. Fox KA, Piccini JP, Wojdyla D et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32: 2387-94.
68. Hohnloser SH, Hijazi Z, Thomas L et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33: 2821-30.
69. Heeringa J, van der Kuip DA, Hofman A et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27: 949-53.
70. Langenberg M, Hellemons BS, van Ree JW et al. Atrial fibrillation in elderly patients: prevalence and comorbidity in general practice. BMJ 1996; 313: 1534.
71. Mant J, Hobbs FD, Fletcher K et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493-503.
72. Singer DE, Chang Y, Fang MC et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151: 297-305.
73. Palareti G, Salomone L, Cavazza M et al. Stroke/thromboembolism and intracranial hemorrhage in a 'real world' atrial fibrillation population: the CAFBO STUDY (Complications of Atrial Fibrillation in the BOlogna area). Chest 2014; 146: 1073-80.
74. Hylek EM, D'Antonio J, Evans-Molina C et al. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke 2006; 37: 1075-80.
75. Goudie BM, Donnan PT, Fairfield G et al. Dependency rather than old age increases the risk of warfarin-related bleeding. Br J Gen Pract 2004; 54: 690-2.
76. Man-Son-Hing M, Nichol G, Lau A et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999; 159: 677-85.
77. Sardar P, Chatterjee S, Chaudhari S et al. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc 2014; 62: 857-64.
78. Eikelboom JW, Wallentin L, Connolly SJ et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363-72.
79. Senoo K, Lane D, Lip GYH. Oral anticoagulants for stroke prevention in atrial fibrillation: anticoagulants in atrial fibrillation. Curr Probl Cardiol 2014; 39: 319-44.
80. Verdecchia P, Angeli F, Lip GY et al. Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons. PLoS One 2014; 9: e100478.
81. Investigators AWGotA, Connolly S, Pogue J et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903-12.
82. Investigators A, Connolly SJ, Pogue J et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360: 2066-78.
83. Olesen JB, Lip GY, Hansen PR et al. Bleeding risk in 'real world' patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost 2011; 9: 1460-7.
84. Nieuwlaat R, Capucci A, Camm AJ et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26: 2422-34.
85. Hamm CW, Bassand JP, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054.
86. Task Force on the management of STseamiotESoC, Steg PG, James SK et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-619.
87. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25: 457-507.
88. Olesen JB, Gislason GH, Torp-Pedersen C et al. Atrial fibrillation and vascular disease-a bad combination. Clin Cardiol 2012; 35(Suppl 1): 15-20.
89. De Caterina R, Ammentorp B, Darius H et al. Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. Heart 2014; 100: 1625-35.
90. Lip GY, Windecker S, Huber K et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014; 35: 3155-79.
91. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172: 397-402.
92. Hori M, Connolly SJ, Ezekowitz MD et al. Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation-sub-analysis in Japanese population in RE-LY trial. Circ J 2011; 75: 800-5.
93. Hohnloser SH, Oldgren J, Yang S et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 2012; 125: 669-76.
94. Hokusai VTEI, Buller HR, Decousus H et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406-15.
95. Mega JL, Braunwald E, Wiviott SD et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19.
96. Ducrocq G, Bhatt D, Labreuche J et al. Geographic differences in outcomes in outpatients with established atherothrombotic disease: results from the REACH Registry. Eur J Prev Cardiol 2014; 21: 1509-16.
97. Goto S, Oh S, Cools F et al. Regional differences in use of antithrombotic therapy for stroke prevention in atrial fibrillation and associated outcomes: European and Asian insights. Eur Heart J 2013; 34(Suppl 1): 790-1.
98. Sabir I, Khavandi K, Brownrigg J et al. Oral anticoagulants for Asian patients with atrial fibrillation. Nat Rev Cardiol 2014; 11: 290-303.
99. Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost 2014; 111: 789-97.
100. Koretsune Y, Yamashita T, Yang Y et al. Edoxaban vs warfarin in East Asian (including Japanese) patients with atrial fibrillation - an ENGAGE AF-TIMI 48 subanalysis. Abstract: presented at the Japanese Circulation Society 2014 Annual Scientific Meeting, 2014.
101. Hori M, Matsumoto M, Tanahashi N et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation - the J-ROCKET AF study. Circ J 2012; 76: 2104-11.
102. Hori M, Connolly SJ, Zhu J et al. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 2013; 44: 1891-6.
103. Albertsen IE, Rasmussen LH, Overvad TF et al. Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta-analysis. Stroke 2013; 44: 1329-36.
104. Ogawa S, Hori M. Urgent statement on antithrombotic therapy of atrial fibrillation. Circ J 2011; 75: 2719-21.
105. Ogawa S, Aonuma K, Tse H-F et al. The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation. J Arrhythm 2013; 29: 190-200.
106. Gomez-Outes A, Terleira-Fernandez AI, Calvo-Rojas G et al. Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups. Thrombosis 2013; 2013: 640723.
107. Oldgren J, Alings M, Darius H et al. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med 2011; 155: 660-7, W204.
108. van Walraven C, Hart RG, Connolly S et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 2009; 40: 1410-6.
109. Thrall G, Lip GY, Carroll D et al. Depression, anxiety, and quality of life in patients with atrial fibrillation. Chest 2007; 132: 1259-64.
110. Thrall G, Lane D, Carroll D et al. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 2006; 119: 448 e1-e19.
111. Lamassa M, Di Carlo A, Pracucci G et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke 2001; 32: 392-8.
112. Mohammed MA, Marshall T, Nirantharakumar K et al. Patterns of warfarin use in subgroups of patients with atrial fibrillation: a cross-sectional analysis of 430 general practices in the United Kingdom. PLoS One 2013; 8: e61979.
113. Lang K, Bozkaya D, Patel AA et al. Anticoagulant use for the prevention of stroke in patients with atrial fibrillation: findings from a multi-payer analysis. BMC Health Serv Res 2014; 14: 329.
114. Ingelgard A, Hollowell J, Reddy P et al. What are the barriers to warfarin use in atrial fibrillation?: development of a questionnaire. J Thromb Thrombolysis 2006; 21: 257-65.
115. Aliot E, Breithardt G, Brugada J et al. An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality. Europace 2010; 12: 626-33.
116. Edwards A, Elwyn G, Mulley A. Explaining risks: turning numerical data into meaningful pictures. BMJ 2002; 324: 827-30.
117. NICE NIfHaCE. Atrial fibrillation: medicines to help reduce your risk of a stroke - what are the options?, 2014.
118. Lahaye S, Regpala S, Lacombe S et al. Evaluation of patients' attitudes towards stroke prevention and bleeding risk in atrial fibrillation. Thromb Haemost 2014; 111: 465-73.
119. Devereaux PJ, Anderson DR, Gardner MJ et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ 2001; 323: 1218-22.
120. Alonso-Coello P, Montori VM, Diaz MG et al. Values and preferences for oral antithrombotic therapy in patients with atrial fibrillation: physician and patient perspectives. Health Expect 2014; doi: 10.1111/hex.12201. [Epub ahead of print].
121. Pugh D, Pugh J, Mead GE. Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing 2011; 40: 675-83.
122. Lip GY, Kamath S, Jafri M et al. Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: the West Birmingham Atrial Fibrillation Project. Stroke 2002; 33: 238-42.